Drug Profile
Research programme: phosphodiesterase type 4 inhibitors - Stiefel
Alternative Names: Atopik; Catramilast; R115500Latest Information Update: 24 Aug 2009
Price :
$50
*
At a glance
- Originator Barrier Therapeutics Inc
- Developer Stiefel Laboratories
- Class Skin disorder therapies; Small molecules
- Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Atopic dermatitis
Most Recent Events
- 30 Mar 2007 Preclinical development is ongoing
- 17 Jun 2004 Preclinical trials in Atopic dermatitis in USA (Topical)